en · de · es · fr · pt
cjc-1295-notes.peptides5388.com › Faq › Structure And Receptor Pharmacology — What the Evidence Shows

Structure And Receptor Pharmacology — What the Evidence Shows

By Editorial Desk · published 2026-07-24 · last reviewed 2026-08-01 · Faq

If you have been reading about GRF(1-29) and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.

Structure And Receptor Pharmacology

CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.

Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.

Receptor Action and Clearance

Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.

Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.

Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.

Cjc-1295 at a glance

PropertyValueNotes
Peptide classSynthetic GHRH analogueBuilt on a 29 residue sequence
Primary targetGHRH receptor (GHRHR)Class B G protein coupled receptor
Unconjugated half lifeMinutesLimited by protease degradation
Key modificationFour residue substitutionsPositions 2, 8, 15 and 27
Common synonymModified GRF(1-29)Usually denotes the form without DAC

Mechanism and Pharmacokinetics

Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.

The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.

Related pages on this site

Background and Molecular Design

The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.

Molecular Background and Naming

CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.

Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.

Handling, Stability and Analysis

Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.

Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.

Notes from published material

=== India === The Indian Armed Forces issues a host of rations including the One Man Combo Pack Ration, Mini Combo Pack, Survival Ration, and Main Battle Tank Rations. The shelf-life of the ration is 12 months. India has adopted retort processing technology for combat rations. The rations use pre-cooked thermostabilized entrees in a plastic-foil laminate retort pouch. The ration does not require cooking and the contents may be eaten cold, though warming is preferred. An entire day's worth of food, plus accessory items, is packed inside a heavy-duty olive green plastic bag with pasted on label. The menu consists of several different Vegetarian and Non-Vegetarian products that cater to Indian tastes, such as sooji halwa, chapatis, tea mix, chicken biryani, chicken curry, Kebab, Tandoori, Panneer, Organic Egg, Butter naan, mutton biryani, Mutton curry, Vegetable biryani, rajma curry, dal fry, jeera rice, Dal makhani, vegetable pulav and mixed vegetable curry, alongside pickled hot seasoning, in small plastic pouches. The One Man Combo Pack consists of early morning tea, breakfast, mid morning tea, lunch, evening tea, and dinner. The menus feature both dehydrated and ready-to-eat products, and include a folding stove and hexamine fuel tablets. The ration weighs 880 grams and provides 4,100 kcal (17,000 kJ). The Mini Combo Pack is a simplified version of the One Man Combo Pack, weighing 400 g and providing 1,520 kcal (6,400 kJ). The Survival Ration consists of a soft bar and chikki.

=== Catalyst support === Diatomaceous earth also finds some use as a support for catalysts, generally serving to maximize a catalyst's surface area and activity. For example, nickel can be supported on the material—the combination is called Ni–Kieselgur—to improve its activity as a hydrogenation catalyst.

=== Idioms === "Not my cup of tea" (not one's choice or preference) "Tea" and "Spilling the tea" is used to refer to salacious or personal information or gossip in African American Vernacular English. Theories regarding the origin of the term vary, with one popular theory being that it originates from the practice of confiding with close friends at tea parties, a common practice in the American South.

Sources: en.wikipedia.org

Background from the literature

== Mechanism of action == Avanafil inhibits phosphodiesterase-5, preventing the degradation of cGMP. The increased levels of cGMP causes vasodilation, resulting in an increased blood flow in the penis. Avanafil's mechanism of action takes place once nitric oxide is released, in association with sexual stimulation.

Some Sanders supporters raised concerns that publications such as The New York Times minimized coverage of the Sanders campaign in favor of other candidates, especially Trump and Clinton. The Times' ombudsman reviewed her paper's coverage of the Sanders campaign and found that as of September 2015 the Times "hasn't always taken it very seriously. The tone of some stories is regrettably dismissive, even mocking at times. Some of that is focused on the candidate's age, appearance and style, rather than what he has to say." She also found that the Times's coverage of Sanders's campaign was much scanter than its coverage of Trump's, though Trump's was also initially considered a long shot at that time, with 63 articles covering the Trump campaign and 14 covering Sanders's. A December 2015 report found that the three major networks—CBS, NBC, and ABC—had spent 234 minutes reporting on Trump and 10 minutes on Sanders, despite their similar polling results. The report noted that ABC World News Tonight had spent 81 minutes on Trump and less than one minute on Sanders during 2015. A study of media coverage in the 2016 election concluded that while Sanders received less coverage than his rival Hillary Clinton, the amount of coverage of Sanders during the election was largely consistent with his polling performance, except during 2015 when Sanders received coverage that far exceeded his standing in the polls.

Gepirone, sold under the brand name Exxua, is a medication used for the treatment of major depressive disorder. It is taken orally. Side effects of gepirone include dizziness, nausea, insomnia, abdominal pain, and dyspepsia (indigestion). Gepirone acts as a partial agonist of the serotonin 5-HT1A receptor. An active metabolite of gepirone, 1-(2-pyrimidinyl)piperazine, is an α2-adrenergic receptor antagonist. Gepirone is a member of the azapirone group of compounds. Gepirone was synthesized by Bristol-Myers Squibb in 1986 and was developed and marketed by Fabre-Kramer Pharmaceuticals. It was approved for the treatment of major depressive disorder in the United States in September 2023. This came after the drug had been rejected by the Food and Drug Administration (FDA) three times over two decades due to insufficient evidence of effectiveness.

Sources: en.wikipedia.org

Reference notes

Meitnerium has no stable or naturally occurring isotopes. Several radioisotopes have been synthesized in the laboratory, either by fusing two atoms or from the decay of heavier elements. Eight isotopes of meitnerium have been reported with mass numbers 266, 268, 270, and 274–278, two of which, 268Mt and 270Mt, have unconfirmed metastable states. A ninth isotope, 282Mt, is unconfirmed. Most of these decay by alpha emission, though some undergo spontaneous fission.

An artificial metalloenzyme (ArM) is a designer metalloprotein, not found in nature, which can catalyze desired chemical reactions. Despite fitting into classical enzyme categories, ArMs also have potential in new-to-nature chemical reactivity like catalysing Suzuki coupling, metathesis etc., which were never reported among natural enzymatic reactions. ArMs have two main components: a protein scaffold and an artificial catalytic moiety, which, in this case, features a metal center. This class of designer biocatalysts is unique because of the potential to improve the catalytic performance through chemogenetic optimization, a parallel improvement of both the direct metal surrounding (first coordination sphere) and the protein scaffold (second coordination sphere).The second coordination sphere (protein scaffold) is easily evolvable and, in the case of ArMs, responsible for very high (stereo)selectivity. With the progress in organometallic synthesis and protein engineering, more and more new kind of design of ArMs were developed, showing promising future in both academia and industrial aspects. In 2018, one-half of the Nobel Prize in Chemistry was awarded to Frances H. Arnold "for the directed evolution of enzymes", who elegantly evolved artificial metalloenzymes to realize efficient and highly selective new-to-nature chemical reactions in vitro and in vivo.

During this period, Humboldt investigated the fate of the Guanches, the indigenous people of the Canaries, concluding that they had been destroyed by European conquest and slavery, with survivors assimilated into the Spanish population. The Pizarro crossed the Tropic of Cancer on June 27, sailing through the Atlantic and carefully avoiding the area labeled “Bank of Maal-strom,” whose dangers Humboldt doubted existed in the calm tropics. The ship passed west of the Cape Verde Islands, once claimed for Portugal by Alvise da Mosto, and entered the Sargasso Sea, a vast region of floating seaweed previously described by Columbus. Here, the crew encountered a partially submerged, abandoned ship covered in seaweed, which Humboldt surmised had drifted from the rough North Atlantic rather than sinking locally. Throughout the voyage, Humboldt and Bonpland conducted systematic scientific observations, measuring a wide array of atmospheric and oceanic variables and recording them meticulously. The two naturalists spent their evenings observing unfamiliar southern constellations, including the Southern Cross, which stirred Humboldt’s sense of distance from Europe. The ship enjoyed a relatively smooth journey across the Atlantic, following established routes aided by predictable trade winds. The calm seas known as el Golfo de las Damas made for easy sailing, and the crew rarely needed to adjust the sails. Approaching the West Indies, the weather changed, with frequent tropical squalls and the distinctive "dark winds," phenomena new to Humboldt but familiar in the region.

Sources: en.wikipedia.org

Frequently asked questions

Is CJC-1295 the same as modified GRF(1-29)?

The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.

What does the acronym DAC refer to?

DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.

Does this peptide occur naturally in the body?

No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.

Which receptor does the compound target?

It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.

Network